LGC to Use Fluidigm's BioMark System in UK Labs | GenomeWeb
NEW YORK (GenomeWeb News) – The life sciences services firm LGC has purchased one of Fluidigm’s BioMark Systems, which it will use to offer genetic analysis services in its United Kingdom labs, Fluidigm said today.
 
The BioMark System uses fluidic circuit technology to improve throughput, reduce complexity, and allow for use of smaller samples and less reagents in high throughput genotyping applications, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.